Evolent Health Q1 revenue down 24% to $483.6M; net loss widens to $72.3M

Evolent Health, Inc.

2025-Q1 EPS reported -$0.63 revenue$483,649,000

Revenue $483.6M vs $639.7M YoY; net loss $72.3M vs $25.2M YoY.
Adjusted EBITDA $36.9M (7.6% margin) vs $54.1M (8.5% margin) YoY.
Five new revenue agreements added, including surgical management, oncology, and imaging expansions.
Performance Suite lives declined to 6,486 from 7,050 YoY; specialty technology lives rose to 77,079.
Company reiterates full-year 2025 revenue and Adjusted EBITDA outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.